Trigeminal neuralgia

Jeito Capital co-leads a EUR 104 million financing in Noema Pharma, a clinical-stage biopharma company targeting debilitating central nervous system disorders

Retrieved on: 
Tuesday, March 7, 2023
Depression, Doctor of Philosophy, Growth, Tourette syndrome, Polaris Partners, Binge eating disorder, INVU (song), CHF, Safety, Trigeminal neuralgia, Tuberous sclerosis complex tumor suppressors, CNS, Knowledge, Capital, Face, Seizure, DSM-IV codes, Drug development, Patient, Sofinnova, News, Central nervous system disease, Do Meu Jeito, MD, Acceleration, UPMC, Fine chemical, Pharmaceutical industry, Noema

USD 112 million) financing in Noema Pharma (the “Company”), a clinical-stage biopharma company targeting debilitating central nervous system (CNS) disorders.

Key Points: 
  • USD 112 million) financing in Noema Pharma (the “Company”), a clinical-stage biopharma company targeting debilitating central nervous system (CNS) disorders.
  • As part of its indication expansion strategy, the Company also anticipates initiating clinical development in Atypical Depression and Binge Eating Disorders.
  • Jeito selected Noema Pharma in line with its investment strategy of supporting the development of the most promising European biopharma companies with high growth and acceleration potential.
  • This financing comes at a key time for Noema Pharma as we look forward to extensive news flow over the next 24 months.”

Noema Pharma, Founded by Sofinnova Partners, Raises CHF 103 Million (USD 112 Million) in Series B Financing

Retrieved on: 
Tuesday, March 7, 2023
Other Professional Services, Biotechnology, Pharmaceutical, Finance, General Health, Health, Professional Services, Clinical Trials, Polaris Partners, PDE10A, Partner, Atypical depression, Series A round, Tuberous sclerosis complex tumor suppressors, Sofinnova, News, COFD, CHF, Central nervous system disease, Patient, INVU (song), Tourette syndrome, TSC, Glutamate (neurotransmitter), CNS, Pain, Depression, Series, Seizure, Stuttering, Trigeminal neuralgia, Pharmaceutical industry, Noema

Sofinnova Partners (“Sofinnova"), a leading European life sciences venture capital firm based in Paris, London, and Milan, today announced that Noema Pharma (“Noema”), has raised an oversubscribed CHF 103 million (approx.

Key Points: 
  • Sofinnova Partners (“Sofinnova"), a leading European life sciences venture capital firm based in Paris, London, and Milan, today announced that Noema Pharma (“Noema”), has raised an oversubscribed CHF 103 million (approx.
  • This financing comes at a key time for Noema Pharma as we look forward to extensive news flow over the next 24 months.”
    The Series B financing follows a CHF 54 million (approx.
  • USD 60 million) Series A financing concluded in December 2020, led by Sofinnova Partners and Polaris Partners.
  • Noema Pharma was founded in 2019 with a seed investment from Sofinnova Partners and four clinical stage assets in-licensed from Roche.

Centura Littleton Adventist Hospital First in Region to Use Innovative Non-Invasive Treatment for Brain Tumors

Retrieved on: 
Wednesday, January 25, 2023
Zap, Leeds Gamma Knife Centre, Skull, Patient, Dizziness, Cobalt, AdventHealth, Schwannoma, Radiosurgery, Rocky Mountains, Quality of life, Neurosurgery, Hearing loss, Brain, Health, Trigeminal neuralgia, Neck, Neoplasm, Centura, ZAPX, Head, Radiation, Skiing, Pain, Medical imaging

The outpatient procedure was first performed at Littleton Adventist Hospital on a 71-year-old man with a benign tumor that was causing symptoms affecting his quality of life.

Key Points: 
  • The outpatient procedure was first performed at Littleton Adventist Hospital on a 71-year-old man with a benign tumor that was causing symptoms affecting his quality of life.
  • Using Zap-X, Dr. Adair Prall with Neurosurgery One, a Centura clinic based at Littleton Adventist, was able to focus intense beams of radiation to treat the tumor while avoiding healthy surrounding tissue.
  • The technology can be used to treat many types of brain tumors and other conditions in the brain, head and neck.
  • Radiosurgery can be used to treat patients with trigeminal neuralgia, brain tumors, and other types of benign tumors such as acoustic neuromas.

Clinical trial to test wearable device as treatment for chronic pain, opioid withdrawal

Retrieved on: 
Tuesday, January 17, 2023
Neuroimaging, Addiction, Tan, Brain, University, Vagus nerve stimulation, Anesthesiology, Doctor of Philosophy, Trigeminal nerve, Department of Pharmacology, University College London, Tandem, Principal investigator, Chronic pain, Psychiatry, FDA, Research, Trigeminal neuralgia, UTMB, Death, VNS, History, Patient, Behavioural sciences, Howard Brody, Stroke, Analgesic, Cranial nerves, Pain, TNS, Medical University of South Carolina, MUSC, Vagus nerve, Magnetic resonance, Pain management, Medical school, Opioid use disorder, Dentistry, Pharmaceutical industry, Cereal, Medical imaging, Sparrow, Pharmacology

“Our collaborative project will determine the efficacy of tAN to ease tapering of real-world patients from opioid management of chronic pain with reduced withdrawal symptoms.

Key Points: 
  • “Our collaborative project will determine the efficacy of tAN to ease tapering of real-world patients from opioid management of chronic pain with reduced withdrawal symptoms.
  • Importantly, neurostimulation therapy will provide a much needed and innovative treatment option over existing opioid analgesics with high risk for misuse, opioid use disorder, and overdose.”
    Amid the opioid epidemic, a treatment chasm has emerged.
  • Countless patients are being encouraged to avoid or discontinue opioid use for acute pain relief and chronic pain conditions for which opioids are a daily necessity.
  • Spark Biomedical developed the Sparrow Therapy System—the first FDA-cleared wearable, non-invasive tAN device for the treatment of opioid withdrawal.

Acasti Pharma Discusses Positive Clinical Study Results for GTX-101 and GTX-102 and Upcoming Phase 3 Study for GTX-104 with The Stock Day Podcast

Retrieved on: 
Tuesday, January 17, 2023
Disease, News, Infection, SAH, Interview, Absorption, Trial of the century, ACST, Bupivacaine, Safety, FDA, Skin, Nimodipine, Betamethasone, PHN, Trigeminal neuralgia, Subarachnoid hemorrhage, Pharmaceutical industry

"Acasti is a specialty pharmaceutical company, and we are focused on developing drugs for rare and orphan diseases," explained D'Alvise.

Key Points: 
  • "Acasti is a specialty pharmaceutical company, and we are focused on developing drugs for rare and orphan diseases," explained D'Alvise.
  • "Could you tell us about the recent results you received for the GTX-101 study?," asked Jolly.
  • "Our clinical data shows that there is not only a rapid onset of action, but also a sustained release profile."
  • "We have developed a concentrated oral spray, which is rapidly absorbed," she said, before discussing the results of the Company's clinical study.

Kriya Acquires Redpin Therapeutics, Adding Neurology Pipeline to Gene Therapy Portfolio

Retrieved on: 
Wednesday, November 16, 2022
Health, Genetics, Research, Pharmaceutical, Science, Biotechnology, FDA, National Organization for Rare Disorders, Nervous system, Ophthalmology, Brain, Investment, Biotechnology, Entrepreneurship, Therapy, Hyperkinesia, Drug development, Epilepsy, Trigeminal neuralgia, Howard Hughes Medical Institute, Multimedia, Conditional sentence, NORD, Triangle Park (Quezon City), Death, Acquisition, Disease, Central nervous system, Neuron, Neurological disorder, Ion, Neurology, SUDEP, Silicon, Pain scale, Patient, Pharmaceutical industry, Kriyā

Kriya Therapeutics, Inc. , a fully integrated gene therapy company advancing a broad portfolio of innovative therapeutics, today announced the acquisition of Redpin Therapeutics, Inc. , a privately held biotechnology company developing regulatable gene therapies for intractable diseases of the nervous system.

Key Points: 
  • Kriya Therapeutics, Inc. , a fully integrated gene therapy company advancing a broad portfolio of innovative therapeutics, today announced the acquisition of Redpin Therapeutics, Inc. , a privately held biotechnology company developing regulatable gene therapies for intractable diseases of the nervous system.
  • The acquisition serves as the foundation for Kriyas neurology therapeutic area portfolio, with two lead gene therapy programs focused on epilepsy and trigeminal neuralgia (TN).
  • Kriya is a fully integrated company pioneering novel technologies and therapeutics in gene therapy.
  • The company is advancing a deep and diversified pipeline of innovative gene therapies in multiple therapeutic area divisions, with current pipeline programs in metabolic disorders, neurology and ophthalmology.

American Shared Hospital Services Reports 18% Period-over-Period Increase in Third Quarter 2022 Revenue to $4.8 Million

Retrieved on: 
Thursday, November 10, 2022
SAN, GLOBE, Review, Income, Trigeminal neuralgia, Marketing, NYSE, Leadership, PBRT, Proton therapy, U.S. Securities and Exchange Commission, HVS Global Hospitality Services, Orlando Health, Century, Annual general meeting, Radiosurgery, Leeds Gamma Knife Centre, Risk, Depreciation, Webcast, Loss, Malignancy, Annual report, CA, EBITDA, AMS, Contract, Pectus carinatum, Company, Home After Three Months Away, Nine Months, ASHS, GAAP, IGRT, Growth, Security (finance), VP, IMRT, CMS, COVID-19, Lithium, Video game, Health insurance, Pharmaceutical industry, Medical imaging, Bookkeeping, Bank

SAN FRANCISCO, CA, Nov. 10, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- American Shared Hospital Services (NYSE American: AMS) (the "Company"), a leading provider of turnkey technology solutions for stereotactic radiosurgery and advanced radiation therapy equipment and services, today announced financial results for the third quarter and nine months of fiscal 2022, ended September 30, 2022.

Key Points: 
  • The gross margin percentage expanded 470 basis points to 40.5% of revenue compared to 35.8% for the third quarter of 2021.
  • Operating income for the third quarter of 2022 was $448,000 compared to operating income of $186,000 in the third quarter of 2021, an increase of 140.9%.
  • Adjusted EBITDA, a non-GAAP financial measure, was $1,999,000 for the third quarter of 2022, compared to $1,562,000 for the third quarter of 2021, an increase of 28.0%.
  • Cash at September 30, 2022 was $11,664,000, an increase of $3,401,000 from the December 31, 2021 balance of $8,263,000.

Lexicon Pharmaceuticals Highlights Oral Presentation of Final Results From the RELIEF-DPN-1 Trial of LX9211 at the 16th Annual Pain Therapeutics Summit

Retrieved on: 
Tuesday, November 8, 2022
GLOBE, Protein, Intellectual property, U.S. Securities and Exchange Commission, Pharmacokinetics, Food, Nasdaq, Diabetes, Webcast, Annual report, AAK1, Gene, Drug discovery, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Therapy, Heart failure, Efficacy, Fast Track, Diabetic neuropathy, ID, Trigeminal neuralgia, Form 10-K, Disease, Program, Neuropathic pain, Patient, Treatment, Growth, Security (finance), Bristol Myers Squibb, Metabolism, Trial of the century, Pharmaceutical industry, Safety, Lexicon

The presentation will describe the preclinical basis for the program, the framework of the trial, and an analysis of the final results from this successful proof-of-concept study.

Key Points: 
  • The presentation will describe the preclinical basis for the program, the framework of the trial, and an analysis of the final results from this successful proof-of-concept study.
  • Following the presentation, Dr. Patel will join Lexicon management on a live conference call and webcast at 5:00pm ET to discuss the study results.
  • The dial-in number for the conference call is 888-886-7786 and the conference ID for all callers is 28989106.
  • Preclinical studies of LX9211 demonstrated central nervous system penetration and reduction in pain behavior in models of neuropathic pain without affecting opiate pathways.

American Shared Hospital Services Announces Third Quarter 2022 Earnings Conference Call

Retrieved on: 
Thursday, November 3, 2022
Proton therapy, Company, CA, Pectus carinatum, Call, GLOBE, Trigeminal neuralgia, NYSE, IGRT, Pain scale, IMRT, AMS, Radiosurgery, Malignancy, Medical imaging, Conference

SAN FRANCISCO, CA, Nov. 03, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – American Shared Hospital Services (NYSE American: AMS) (the "Company"), a leading provider of turnkey technology solutions for stereotactic radiosurgery and advanced radiation therapy equipment and services, today announced that the Company will hold a quarterly conference call to discuss its third quarter 2022 financial results on Thursday November 10th, 2022 at 3:00 pm ET / 12:00 pm PT. The third quarter 2022 financial results press release will be issued before the market open on Thursday, November 10, 2022.

Key Points: 
  • Conference Call on Thursday November 10th, 2022 at 3:00 pm ET / 12:00 pm PT
    SAN FRANCISCO, CA, Nov. 03, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire American Shared Hospital Services (NYSE American: AMS) (the "Company"), a leading provider of turnkey technology solutions for stereotactic radiosurgery and advanced radiation therapy equipment and services, today announced that the Company will hold a quarterly conference call to discuss its third quarter 2022 financial results on Thursday November 10th, 2022 at 3:00 pm ET / 12:00 pm PT.
  • The third quarter 2022 financial results press release will be issued before the market open on Thursday, November 10, 2022.
  • To participate, please call 1 (844) 413-3972 at least 10 minutes prior to the start of the call and ask to join the American Shared Hospital Services call.
  • About American Shared Hospital Services (NYSE American: AMS)
    American Shared Hospital Services is a leading provider of turnkey technology solutions for stereotactic radiosurgery and advanced radiation therapy equipment and services.

Lexicon Pharmaceuticals Announces Oral Presentations Relating To Its LX9211 Neuropathic Pain Program At The World Brain Disorders And Neuroscience Summit 2022

Retrieved on: 
Monday, October 24, 2022
U.S. Securities and Exchange Commission, Disease, AAK1, Multiple sclerosis, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Patient, Trigeminal neuralgia, Neuroscience, Security (finance), Annual report, Nasdaq, Gene, Form 10-K, Food, Treatment, Trial of the century, Drug discovery, Bristol Myers Squibb, Pharmacokinetics, Heart failure, Pain, Neuropathic pain, Safety, Diabetes, Protein, Fast Track, GLOBE, Spasticity, Metabolism, Diabetic neuropathy, Pharmaceutical industry, Lexicon

We are excited to share these promising preclinical data, which we plan to submit for publication in a peer-reviewed journal.

Key Points: 
  • We are excited to share these promising preclinical data, which we plan to submit for publication in a peer-reviewed journal.
  • The RELIEF-DPN-1 study was the first of two Phase 2 proof-of-concept studies evaluating LX9211 in neuropathic pain.
  • Preclinical studies of LX9211 demonstrated central nervous system penetration and reduction in pain behavior in models of neuropathic pain without affecting opiate pathways.
  • LX9211 has received Fast Track designation from the U.S. Food and Drug Administration for the development in diabetic peripheral neuropathic pain.